How I treat idiopathic thrombocytopenic purpura (ITP)

Blood

Volumn 106, Issue 7, 2005, Pages 2244-2251

  Cines, Douglas B ^a   Bussel, James B ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMG 531; AMINOCAPROIC ACID; ANTICOAGULANT AGENT; AZATHIOPRINE; CLOPIDOGREL; COLLAGEN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DANAZOL; DAPSONE; DESMOPRESSIN ACETATE; FIBRIN; GESTAGEN; IMMUNOGLOBULIN G; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; PROTON PUMP INHIBITOR; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RHESUS D ANTIBODY; RITUXIMAB; STEROID; THROMBIN; TRANEXAMIC ACID; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE; WARFARIN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ACUTE KIDNEY FAILURE; ADRENAL INSUFFICIENCY; AMINOTRANSFERASE BLOOD LEVEL; ASEPTIC MENINGITIS; BLEEDING; BONE MARROW EXAMINATION; CHILL; CLINICAL FEATURE; CYTOGENETICS; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG INDUCED HEADACHE; DRUG SAFETY; EMERGENCY TREATMENT; FEVER; HEMOLYSIS; HIRSUTISM; HOSPITALIZATION; HUMAN; HYPERTENSION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOGLOBULIN BLOOD LEVEL; INFECTION; LUNG INSUFFICIENCY; MALIGNANT NEOPLASTIC DISEASE; MENORRHAGIA; MENSTRUATION DISORDER; MOOD DISORDER; MYALGIA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PREGNANCY; PRIORITY JOURNAL; PROSTATE DISEASE; RASH; REVIEW; SPLENECTOMY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOSIS;

EID: 27144509749     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2004-12-4598     Document Type: Review

References (92)

1. George JN, Vesely SK. How can we provide the best care for our patients with immune thrombocytopenic purpura? Mayo Clinic Proc. 2004;79:456-457.
2. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood. 1996;88:3-46.
3. Provan D, Newland A, Bolton-Maggs P, et al. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol. 2003;120:574-596.
4. Bussel JB, Cines DB. Immune thrombocytopenic purpura, neonatal alloimmune thrombocytopenia, and post-transfusion purpura. In: Hoffman R, Benz EJ Jr, Shattil SJ, et al, eds. Hematology. Basic Principles and Practice. Philadelphia, PA: Elsevier-Churchill Livingstone;2004:2269-2286.
5. Cines DB, Blanchette V. Idiopathic thrombocytopenic purpura. N Engl J Med. 2002;364:995-1008.
6. Doan CA, Bouroncle BA, Wiseman BK. Idiopathic and secondary thrombocytopenic purpura: clinical study and evaluation of 381 cases over a period of 28 years. Ann Intern Med. 1960;53:861-876.
7. Stasi R, Stipa E, Masi M, et al. Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. Am J Med. 1995;98:436-4442.
8. Frederiksen H, Schmidt K. The incidence of idiopathic thrombocytopenic purpura in adults increases with age. Blood. 1999;94:909-913.
9. Neylon AJ, Saunders PWG, Howard MR, Proctor SJ, Taylor PRA, on behalf of the Northern Regional Haematology Group. Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients. Br J Haematol. 2003;122:966-974.
10. Aledort LM, Hayward CP, Chen MG, Nichol JL, Bussel J. Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodies. Am J Hematol. 2004;76:205-213.
11. Sashida G, Ohyashiki JH, Ito Y, Ohyashiki K. Monoclonal constitution of neutrophils detected by PCR-based human androgen receptor gene assay in a subset of idiopathic thrombocytopenic purpura patients. Leuk Res. 2002;26:825-830.
12. Zhang L, Li H, Zhao H, Ji L, Yang R. Hepatitis C virus-related adult chronic idiopathic thrombocytopenic purpura: experience from a single Chinese center. Eur J Haematol. 2004;70:196-197.
13. Emilia G, Longo G, Luppi M, et al. Helicobacter pylori eradication can induce platelet recovery in idiopathic thrombocytopenic purpura. Blood. 2001;97:812-814.
14. Kohda K, Kuga T, Kogawa K, et al. Effect of Helicobacter pylori eradication on platelet recovery in Japanese patients with chronic idiopathic thrombocytopenic purpura and secondary autoimmune thrombocytopenic purpura. Br J Haematol. 2002;118:584-588.
15. Michel M, Cooper N, Jean C, Frissora C, Bussel JB. Does Helicobacter pylori initiate or perpetuate immune thrombocytopenic purpura? Blood. 2003;103:890-896.
16. Diz-Kucukkaya R, Hacihanefioglu A, Yenerel M, et al. Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort study. Blood. 2001;98:1760-1764.
17. Portiejle JEA, Westendorp RGJ, Kluin-Nelemans HC, Brand A. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood. 2001;97:2549-2554.
18. Brighton TA, Evans S, Castaldi PA, Chesterman CN, Chong BH. Prospective evaluation of usefulness of an antigen-specific assay (MAIPA) in idiopathic thrombocytopenic purpura and other immune thrombocytopenia. Blood. 1996;88:194-201.
19. Warner MN, Moore JC, Warkentin TE, Santos AV, Kelton JG. A prospective study of protein-specific assays used to investigate idiopathic thrombocytopenic purpura. Br J Haematol. 1999;104:442-447.
20. McMillan R, Wang L, Tani P. Prospective evaluation of the immunobead assay for the diagnosis of adult chronic immune thrombocytopenic purpura (ITP). J Thromb Haemost. 2003;1:485-491.
21. Berchtold P, Muller D, Beardsley D, et al. International study to compare antigen-specific methods used for the measurement of antiplatelet autoantibodies. Br J Haematol. 1997;96:477-481.
22. Vianelli N, Valdre L, Fiacchini M, et al. Long-term follow-up of idiopathic thrombocytopenic purpura in 310 patients. Haematologica. 2001;86:504-509.
23. Cohen YC, Djulbegovic B, Shamai-Lubovitz O, Mozes B. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Intern Med. 2000;160:1630-1638.
24. Cortelazzo S, Finazzi G, Buelli M, Molteni A, Viero P, Barbui T. High risk of severe bleeding in aged patients with chronic idiopathic thrombocytopenic purpura. Blood. 1991;77:31-33.
25. Bourgeois E, Caulier MT, Delarozee C, Brouillard M, Bauters F, Fenaux P. Long-term follow-up of chronic autoimmune thrombocytopenic purpura refractory to splenectomy: a prospective analysis. Br J Haematol. 2003;120:1079-1088.
26. McMillan R, Durette C. Long-term outcomes in adults with chronic ITP after splenectomy failure. Blood. 2004;104:956-960.
27. Lee MS, Kim WC. Intracranial hemorrhage associated with idiopathic thrombocytopenic purpura: report of seven patients and a meta-analysis. Neurology. 1998;50:1160-1163.
28. George JN. Idiopathic thrombocytopenic purpura in adults: current issues for pathogenesis, diagnosis and management. Hematol J. 2004;5:S12-S14.
29. McMillan R, Bowditch RD, Tani P, Anderson H, Goodnight S. A non-thrombocytopenic bleeding disorder due to an IgG4-kappa anti-GPIIb/IIIa autoantibody. Br J Haematol. 1996;95:747-749.
30. Cines DB, McMillan R. Management of adult idiopathic thrombocytopenic purpura. Annu Rev Med. 2005;56:425-442.
31. Godeau B, Chevret S, Varet B, et al. Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomised, multicenter trial. Lancet, 2002;359:23-29.
32. von dem Borne AEGK, Vos JJE, Pegels JG, Thomas LLM, van der Lelie H. High dose intravenous methylprednisolone or high dose intravenous gammaglobulin for autoimmune thrombocytopenia. BMJ. 1988;296:249-260.
33. Gaines AR. Acute onset of hemoglobinemia and/or hemoglobinuria and sequelae following Rho(D) immune globulin intravenous administration in immune thrombocytopenic purpura patients. Blood. 2000;95:2523-2529.
34. Samuelsson A, Towers TL, Ravetch JV. Anti-in-flammatory activity of IVIG mediated through the inhibitory Fc receptor. Science. 2001;291:484-486.
35. Crow AR, Song S, Freedman J, et al. IVIg-mediated amelioration of murine ITP via FcγRIIB is independent of SHIP1, SHP-1, and Btk activity. Blood. 2003;102:558-560.
36. Song S, Crow AR, Siragam V, Freedman J, Lazarus AH. Monoclonal antibodies that mimic the action of anti-D in the amelioration of murine ITP act by a mechanism distinct from that of IVIg. Blood. 2005;105:1546-1548.
37. Gururangan S, Bussel JB. Combination immunotherapy for patients with refractory ITP or Evan's syndrome (ES) [abstract]. Blood. 1998;92(suppl 1):3345.
38. Baumann MA, Menitove JE, Aster RH, Anderson T. Urgent treatment of idiopathic thrombocytopenic purpura with single-dose gammaglobulin infusion followed by platelet transfusion. Ann Intern Med. 1986;104:808-809.
39. Culic S. Recombinant Factor VIIa for refractory haemorrhage in autoimmune idiopathic thrombocytopenic purpura. Br J Haematol. 2003;120:909-910.
40. Newman GC, Novoa MV, Fodero EM, Lesser ML, Woloski BMR, Bussel JB. A dose of 75 μg/kg/d of IV anti-D increases the platelet count more rapidly and for a longer period of time than does 50 μg/kg/d in adults with immune thrombocytopenic purpura (ITP). Br J Haematol. 2001;112:1076-1078.
41. George JN, Raskob GE, Vesely SK, et al. Initial management of immune thrombocytopenic purpura in adults: a randomized controlled trial comparing intermittent anti-D with routine care. Am J Hematol. 2003;74:161-169.
42. Cheng Y, Wong RSM, Soo YOY, et al. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N Engl J Med. 2003;349:831-836.
43. DiFino SM, Lachant NA, Kirshner JJ, Gottlieb AJ. Adult idiopathic thrombocytopenic purpura: clinical findings and response to therapy. Am J Med. 1980;69:430-442.
44. den Ottolander GJ, Gratama JW, de Koning J, Brand A. Long-term follow-up study of 168 patients with immune thrombocytopenic purpura. Scand J Haematol. 1984;32:101-110.
45. McMillan R. Therapy for adults with refractory chronic immune thrombocytopenic purpura. Ann Intern Med. 1997;126:307-314.
46. Leung AYH, Chim CS, Kwong YL, Lie AKW, Au WY, Liang R. Clinicopathologic and prognostic features chronic idiopathic thrombocytopenic purpura in adult Chinese patients: an analysis of 220 cases. Ann Hematol. 2001;80:384-386.
47. Cooper N, Woloski BMR, Fodero EM, Novoa M, Leber M, Bussel JB. Does treatment with intermittent infusions of IV anti-D allow a proportion of adults with recently diagnosed immune thrombocytopenic purpura (ITP) to avoid splenectomy? Blood. 2002;99:1922-1927.
48. Kojouri K, Vesely SK, Terrell DR, George JN. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood. 2004;104:2623-2634.
49. Schwartz J, Eldor A, Gillis S, Guinta A, Leber M, Bussel JB. Long term follow-up after splenectomy performed for immune thrombocytopenic purpura (ITP). Am J Hematol. 2003;72:94-98.
50. Fabris F, Tassan T, Ramon R, et al. Age as the major predictor of long-term response to splenectomy in immune thrombocytopenic purpura. Br J Haematol. 2001;112:637-640.
51. Bussel J, Cines DB. Idiopathic thrombocytopenic purpura, neonatal alloimmune thrombocytopenia, and post-transfusion purpura. In: Hoffman R, Benz EJ Jr, Shattil SJ, et al, eds. Hematology: Basic Principles and Practice. Philadelphia, PA: Churchill Livingstone, 2000:2096-2114.
52. Najean Y, Rain J-D, Billotey C. The site of destruction of autologous 111In-labelled platelets and the efficiency of splenectomy in children and adults with idiopathic thrombocytopenic purpura: a study of 568 patients with 268 splenectomies. Br J Haematol. 1997;97:547-550.
53. Marcaccio MJ. Laparoscopic splenectomy in chronic idiopathic thrombocytopenic purpura. Semin Hematol. 2000;37:267-274.
54. Calverley DC, Jones GW, Kelton JG. Splenic radiation for corticosteroid-resistant immune thrombocytopenia. Ann Intern Med. 1992;116:977-981.
55. Lortan JE. Management of asplenic patients. Br J Haematol. 1993;84:566-569.
56. Recommendations of the Advisory Committee on Immunization Practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence. MMWR Morb Mortal Wkly Rep. 1993;42:1-11.
57. American Academy of Pediatrics Committee on Infectious Diseases. Policy statement: recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis (RE9960). Pediatrics. 2000;106:362-366.
58. Vesely SK, Perdue JJ, Rizvi MA, Terrell DR, George JN. Management of adult patients with persistent idiopathic thrombocytopenic purpura following splenectomy. Ann Intern Med. 2003;140:112-120.
59. Scaradavou A, Woo B, Woloski BMR, et al. Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients. Blood. 1997;89:2689-2700.
60. Stasi R, Pagano A, Stipa E, Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood. 2001;98:952-957.
61. Cooper N, Stasi R, Cunningham-Randles S, et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenia purpura. Brit J Haematol. 2004;125:232-239.
62. Levy AS, Cunningham-Rundles S, Mazza B, Simm M, Gorlick R, Bussel J. High P-glycoprotein-mediated export observed in patients with a history of idiopathic thrombocytopenic purpura. Br J Haematol. 2002;118:836-838.
63. Hou P, Pang J, Shi Y, et al. Mycophenolate mofetil (MMF) for the treatment of steroidresistant idiopathic thrombocytopenic purpura. Eur J Haematol. 2003;70:353-357.
64. Howard J, Hoffbrand AV, Prentice HG, Mehta A. Mycophenolate mofetil for the treatment of refractory auto-immune haemolytic anemia and auto-immune thrombocytopenia purpura. Br J Haematol 2002;117:712-715.
65. Maloisel F, Andres E, Zimmer J, et al. Danazol therapy in patients with chronic idiopathic thrombocytopenic purpura: long-term results. Am J Med. 2004;116:590-594.
66. Godeau B, Durand J-M, Roudot-Thoraval F, et al. Dapsone for chronic autoimmune thrombocytopenic purpura: a report of 66 cases. Br J Haematol. 1997;97:336-339.
67. Reiner A, Gernsheimer T, Schlichter SJ. Pulse cyclophosphamide therapy for refractory autoimmune thrombocytopenic purpura. Blood. 1995;85:351-358.
68. Kappers-Klunne MC, van't Veer MB. Cyclosporin A for the treatment of patients with chronic idiopathic thrombocytopenia purpura refractory to corticosteroids or splenectomy. Br J Haematol. 2001;114:121-125.
69. Figueroa M, Gehlsen J, Hammond D, et al. Combination chemotherapy in refractory immune thrombocytopenic purpura. N Engl J Med. 1993;328:1226-1229.
70. McMillan R. Long-term outcomes after treatment for refractory immune thrombocytopenic purpura. N Engl J Med. 2001;344:1402-1403.
71. Nomura S, Kazuo D, Tomomitsu H, Fujimura K, Ikeda Y. Effects of pegylated recombinant human megakaryocyte growth and development factor patients with idiopathic thrombocytopenic purpura. Blood. 2002;100:728-730.
72. Kuter D, Bussel JB, Aledort LM, et al. A phase 2 placebo controlled study evaluating the platelet response and safety of weekly dosing with a novel thrombopoietic protein (AMG531) in thrombocytopenic adult patients (pts) with immune thrombocytopenic purpura (ITP) [abstract]. Blood. 2004;114:S1:148a.
73. Newland A, Caulier MT, Schipperus MR, et al. An open-label, unit dose-finding study evaluating the safety and platelet response of a novel thrombopoietic protein (AMG531) in thrombocytopenic adult patients (pts) with immune thrombocytopenic purpura (ITP) [abstract]. Blood 2004;104:S1:567a.
74. Huhn RD, Fogarty PF, Nakamura R, et al. Highdose cyclophosphamide with autologous lymphocyte-depleted peripheral blood (PBSC) support for treatment of refractory chronic autoimmune thrombocytopenia. Blood. 2002;101:71-77.
75. Webert KE, Mittal R, Sigouin C, Heddle NM, Kelton JG. A retrospective, 11-year analysis of obstetrical patients with idiopathic thrombocytopenic purpura. Blood. 2003;102:4306-4311.
76. Gill KK, Kelton JG. Management of idiopathic thrombocytopenic purpura in pregnancy. Semin Hematol. 2000;37:275-289.
77. McCrae KR, Samuels P, Schreiber AD. Pregnancy-associated thrombocytopenia: pathogenesis and management. Blood. 1992;80:2697-2714.
78. Burrows RF, Kelton JG. Fetal thrombocytopenia and its relation to maternal thrombocytopenia. N Engl J Med. 1993;329:1463-1466.
79. Letsky EA, Greaves M. Guidelines on the investigation and management of thrombocytopenia in pregnancy and neonatal alloimmune thrombocytopenia. Br J Haematol. 1996;95:21-26.
80. Fujimura K, Harada Y, Fujimoto T, et al. Nationwide study of idiopathic thrombocytopenic purpura in pregnant women and the clinical influence on neonates. Int J Hematol. 2001;75:426-433.
81. Michel M, Novoa MV, Bussel JB. Intravenous anti-D as a treatment for immune thrombocytopenic purpura (ITP) during pregnancy. Br J Haematol. 2003;123:142-146.
82. Cooper N, Heddle NM, Haas M, et al. Intravenous (IV) anti-D and IV immunoglobulin achieve acute platelet increases by different mechanisms: modulation of cytokine and platelet responses to IV anti-D by FcγRIIa and FcγRIIIa polymorphisms. Br J Haematol. 2004;124:511-518.
83. Rosenkrantz JG, Githens JH, Cox SM, Kellum DL. Azathioprine (Imuran) and pregnancy. Am J Obstet Gynecol 1967;97:387-394.
84. Koren G, Pastuszak A, Ito S. Drugs in pregnancy. N Engl J Med 1998;338:1128-1137.
85. Weisz B, Meirow D, Schiff E, Lishner M. Impact and treatment of cancer during pregnancy. Expert Rev Anticancer Ther 2004;4:889-902.
86. Beilin Y, Zahn J, Comerford M. Safe epidural analgesia in thirty parturients with platelet counts between 69,000 and 98,000 mm 3. Anesth Analg. 1997;85:385-388.
87. Burrows RF, Kelton JG. Pregnancy in patients with idiopathic thrombocytopenic purpura: assessing the risks for the infant at delivery. Obstet Gynecol Surv. 1993;46:781-788.
88. Christiaens GCML, Niewenhuis HK, Bussel JB. Comparison of platelet counts in first and second newborns of mothers with immune thrombocytopenic purpura. Obstet Gynecol. 1997;97:893-898.
89. Payne SD, Resnik R, Moore TR, Hedriana HL, Kelly TF. Maternal characteristics and risk of severe neonatal thrombocytopenia and intracranial hemorrhage in pregnancies complicated by autoimmune thrombocytopenia. Am J Obstet Gynecol. 1997;177:149-155.
90. Shashaty GG, Rath CE. Idiopathic thrombocytopenic purpura in the elderly. Am J Med Sci. 1978; 276:263-267.
91. Gaines AR. Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria following Rh0 (D) immune globulin intravenous administration for immune thrombocytopenic purpura. Blood. 2005;106:1532-1537.
92. Shehata N, Burrows R, Kelton JG. Gestational thrombocytopenia. Clin Obstet Gynecol. 1999;42:327-334.